Welcome to our dedicated page for Masimo news (Ticker: MASI), a resource for investors and traders seeking the latest updates and insights on Masimo stock.
Masimo Corporation (NASDAQ: MASI) is a global medical technology company focused on noninvasive patient monitoring, sensors, patient monitors, and automation and connectivity solutions. The Masimo news feed on Stock Titan aggregates company announcements, financial updates, clinical study results, and other material developments that the company discloses through press releases and regulatory communications.
Investors and observers can find news on Masimo e2 80 99s quarterly and annual financial results, including GAAP and non-GAAP revenue, earnings per diluted share, and constant currency revenue growth, as reported in earnings releases and related Form 8-K filings. These updates often include commentary from management on the performance of the healthcare business, operating efficiency initiatives, and guidance for future periods.
Masimo news also covers strategic and corporate actions, such as the completion of the sale of its consumer audio business, Sound United, to Harman International Industries, Incorporated, as disclosed in a September 23, 2025 Form 8-K and related press release. Additional items may include announcements about investor days, participation in healthcare conferences, and updates on long-range financial targets and growth pillars.
Given Masimo e2 80 99s emphasis on clinical evidence and intellectual property, the news flow features results from clinical and feasibility studies involving Masimo SET ae pulse oximetry, including research on performance across different skin tones and in critically ill patients. It also includes statements on significant legal outcomes, such as jury verdicts in patent infringement cases related to Masimo e2 80 99s technologies. By following this page, readers can monitor how Masimo communicates its financial performance, strategic focus on healthcare monitoring, and developments in clinical validation and intellectual property protection.
Masimo (NASDAQ: MASI) provided preliminary fourth-quarter and full-year 2025 financial results ahead of its Feb 26, 2026 full release. Q4 revenue is expected to be approximately $411 million, about 12% reported growth (11% constant currency). Q4 non-GAAP EPS is expected to be more than $1.54, and shipments of noninvasive technology boards and instruments are about 69,000. For full-year 2025, revenue is expected at approximately $1,523 million (about 9% growth) with non-GAAP EPS >$5.55 (the high end of guidance) and shipments of ~270,000. Guidance includes the estimated impact of new tariffs, one additional calendar week, and adjustments for discontinued product lines and distribution model changes.
Masimo (NASDAQ: MASI) said its management will present at the J.P. Morgan 2026 Healthcare Conference on Wednesday, January 14, 2026 at 2:15 p.m. Pacific time.
A live webcast of the presentation will be available on the company website at www.masimo.com, and a replay will be posted following the live presentation.
Masimo (NASDAQ: MASI) hosted its 2025 Investor Day and published a multi-year strategic roadmap through 2028 focused on patient monitoring, technology innovation, and commercial execution.
Key long-range financial targets: Revenue CAGR of 7%–10% through 2028; operating margin ~30% by 2028; adjusted EPS $8.00 by 2028; and cumulative operating cash flow ≈ $1 billion from 2026–2028. Masimo also reaffirmed its 2025 non-GAAP guidance: revenue $1,510–$1,530 million; non-GAAP operating profit $412–$424 million; and non-GAAP diluted EPS $5.40–$5.55.
A replay of the Investor Day webcast is available via the company’s investor site.
Masimo (NASDAQ: MASI) won a patent infringement verdict against Apple after an eight-day jury trial in the U.S. District Court for the Central District of California, with the jury awarding $634,313,913 in damages and finding infringement on all asserted claims.
The case is part of a long-running, multi-venue dispute between the companies; Knobbe Martens led Masimo's trial team and has secured other wins for Masimo, including an import ban on infringing Apple Watches at the U.S. International Trade Commission in early 2024.
Masimo (NASDAQ: MASI) announced a U.S. jury verdict in the Central District of California confirming the validity of Masimo Patent No. 10,433,776, finding that Apple infringed that patent and awarding Masimo $634 million in damages on November 15, 2025. Masimo said it is pleased with the outcome, thanked the court and jury, and emphasized the ruling as a significant win to protect its innovations and intellectual property. The company stated it remains committed to defending its IP rights going forward.
Clairity (MASI) closed a $43 million Series B to commercialize Clairity Breast, described as the first FDA-authorized AI platform that predicts five-year breast cancer risk from routine mammograms. Funds will accelerate U.S. commercialization, expand partnerships with imaging centers and health systems, support reimbursement initiatives, and advance development of Clairity Breast 3D and Clairity Heart for cardiovascular risk prediction from the same imaging exams. The round was led by ACE Global Equity and Santé Ventures, with continued participation from Breast Cancer Research Foundation. Joe Kiani (founder of Masimo) joined as investor and board member.
Masimo (Nasdaq: MASI) reported third quarter 2025 continuing-operations results on November 4, 2025 with GAAP revenue $371.5M (up 8.2% reported) and non-GAAP EPS $1.32 (up 38% year-over-year). Operating margin improved by 450 basis points. Management closed the sale of Sound United and used net proceeds for share repurchases and expanded a strategic partnership with Philips. Updated 2025 non-GAAP guidance: revenue $1,510–1,530M (+8.5% to 10.0% constant currency); EPS $5.62–$5.79 excluding new tariffs and $5.40–$5.55 including estimated tariff impact. Investor Day scheduled for Dec 3, 2025.
Masimo (NASDAQ: MASI) will release third quarter 2025 financial results for the period ended September 27, 2025 after market close on Tuesday, November 4, 2025. The company will host a conference call and webcast the same day at 1:30 p.m. PT / 4:30 p.m. ET, led by CEO Katie Szyman and CFO Micah Young.
Participants must register to receive the dial-in number and registrant ID; registrants will receive email reminders. A replay of the webcast and conference call will be available shortly after the call and archived on the company website.
Masimo (NASDAQ: MASI) will host an Investor Day on Wednesday, December 3, 2025 at 9:00am PT. Presentations by members of the Executive Leadership Team will cover the company’s business overview, market opportunities, innovation pipeline, commercial growth strategy, and long-term financial outlook.
Investors can join via live webcast on the Investor Relations site under Events and Presentations. A replay and related slide presentations will be posted on the company website after the event. In-person attendance is by invitation and requires registration.
Masimo (NASDAQ: MASI) reported results from a feasibility analysis of the INSPIRE trial showing Masimo SET® pulse oximetry performed accurately across a range of skin tones in critically ill adult ICU patients. In the first 50 enrolled patients (80 paired SpO2–SaO2 readings), overall ARMS was 1.47% (below the FDA 1.5% spec and outperforming the 3% industry standard), median bias was -0.6%, and zero occult hypoxemic events were observed. The study used a validated colorimeter to classify skin pigmentation and included 39% of pairs collected during low perfusion. Data collection for the planned 502-patient INSPIRE trial is ongoing.
FAQ
What is the current stock price of Masimo (MASI)?
What is the market cap of Masimo (MASI)?
